Results 141 to 150 of about 4,986,038 (258)

Mobile health interventions to improve adherence to oral anticoagulant treatment: A systematic review and critical analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Non‐adherence to oral anticoagulants (OACs) is associated with significant morbidity and mortality. Mobile health (mHealth) interventions have been used to improve medication adherence across the three phases of initiation, implementation and persistence.
Non Davies   +2 more
wiley   +1 more source

Warfarin time in therapeutic range of primary healthcare patients in the Western Cape Province, South Africa

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction Warfarin therapy is the mainstay of anticoagulation treatment in South Africa and requires frequent INR monitoring due to interindividual patient variability. Time in therapeutic range (TTR) reflects the proportion of total treatment time during which INR values are within therapeutic range.
Masudah Paleker   +3 more
wiley   +1 more source

Implementation and use of risk minimization control tools in the EU: A multistakeholder survey

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study characterized stakeholders' experiences with national implementation of risk minimization control tools (RMCTs), such as healthcare professional qualification, healthcare facility accreditation and medical intervention prior to treatment initiation, for eight medicinal products across eight European Union countries. Methods We conducted
Sharon C. M. Essink   +21 more
wiley   +1 more source

The current landscape of lipoprotein(a) in calcific aortic valvular disease. [PDF]

open access: yesCurr Opin Cardiol, 2021
Hsieh G   +4 more
europepmc   +1 more source

Comparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT).
John K. Bartoli‐Abdou   +10 more
wiley   +1 more source

Pathophysiology and management of valvular disease in patients with destination left ventricular assist devices. [PDF]

open access: yesFront Cardiovasc Med, 2022
Dimarakis I   +6 more
europepmc   +1 more source

Genetic Basis of Valvular Heart Disease

open access: yes
Valvular heart disease is a common cause of heart failure. Identification of the genetic causes of valvular heart disease has important implications in our understanding of these heart diseases, as well as translating these genetic discoveries into ...

core  

CYP3A5 genetic variability influences sildenafil and metabolite in pulmonary hypertension

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Interindividual variability in sildenafil response among pulmonary hypertension patients (PH) may be influenced by CYP3A5 polymorphisms. CYP3A5*3 allele reduces CYP3A5 activity and affects sildenafil metabolism. This study investigated the associations between CYP3A5 genotype and plasma concentrations of sildenafil and N‐desmethyl sildenafil, as ...
Pranisa Wongwien   +7 more
wiley   +1 more source

Alternative access for transapical transcatheter mitral valve implantationCentral Message

open access: yesJTCVS Techniques, 2023
Heinz Deschka, MD   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy